Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference
Scholarly Activity
related documents
-
5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors. Conferences
-
A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies. Conferences
-
A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer. Conferences
-
A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors. Conferences
-
A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy. Conferences
-
A phase II study of durvalumab re-treatment plus /- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A) Conferences
-
A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209. Conferences
-
A randomized study comparing physician-directed or fixed-dose dexamethasone replacement following incomplete steroid premedication for docetaxel chemotherapy. Conferences
-
A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. Conferences
-
Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The Canadian cancer trials group (NCIC CTG) MA.21 experience. Conferences
-
Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). Conferences
-
Ascertaining cancer survivors in Ontario using the Ontario Cancer Registry and administrative data. Conferences
-
Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR plus breast cancer in the TEAM trial. Conferences
-
Association between locoregional failure and NFE2L2/KEAP1/CUL3 pathway mutations in NRG/RTOG 9512: A randomized trial of hyperfractionation vs. conventional fractionation in T2N0 glottic squamous cell carcinoma (SCC). Conferences
-
Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs). Conferences
-
Association of socioeconomic status (SES) with use of specialist palliative care (SPC) among people who died with cancer before and during the COVID-19 pandemic. Conferences
-
CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC). Conferences
-
CCTG PR21: A randomized phase II study of [177lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997) Conferences
-
Can synthetic data accurately mimic oncology clinical trials? Conferences
-
Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and antagonist among patients with advanced prostate cancer. Conferences
-
Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693). Conferences
-
CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. Conferences
-
Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial. Conferences
-
Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naive, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis. Conferences
-
Clinical outcomes of pancreas cancer patients with peritoneal spread: Results from the chord consortium. Conferences
-
Comparing cervical cancer stage at diagnosis in immigrant women and long-term residents. Conferences
-
Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada. Conferences
-
Cost-effectiveness of nodal observation versus completion lymphadenectomy in patients with melanoma and sentinel lymph node metastases. Conferences
-
Cytoreductive surgery (CRS) and heated intra-peritoneal chemotherapy (HIPEC) in the management of peritoneal carcinomatosis in a community setting. Conferences
-
Demonstrating the value of liquid biopsy for lung cancer in a public health care system. Conferences
-
Developing and evaluating new models of care in hematology. Conferences
-
Developing and piloting an electronic telephone triage application. Conferences
-
Dissecting outcomes of patients (pts) with < ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration. Conferences
-
Do women who self-report cognitive symptoms after breast cancer treatment have more cognitive impairment than those who do not report symptoms? A mechanistic cohort study with functional brain MRI. Conferences
-
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy. Conferences
-
Dynamic angiogenic switch as predictor of response to chemotherapy+ bevacizumab in patients with metastatic colorectal cancer. Conferences
-
Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial. Conferences
-
Education modalities for serious illness communication training: A scoping review on the impact on clinician behavior and patient outcomes Conferences
-
Effect of neoadjuvant immunotherapy and targeted therapies on surgical resection in patients with solid tumors: A systematic review and meta-analysis. Conferences
-
Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26. Conferences
-
Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001. Conferences
-
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study. Conferences
-
Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach Conferences
-
Evaluating the impact of Via Pathways (VP) on the adoption of changing treatment paradigms in metastatic hormone-sensitive prostate cancer (mHSPC). Conferences
-
Evaluating the impact of survivorship models on health system resources and costs. Conferences
-
FRACTION-RCC: Innovative, high-throughput assessment of nivolumab plus ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). Conferences
-
First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC). Conferences
-
Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices. Conferences
-
Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. Conferences
-
Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC). Conferences
-
Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) plus /- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC). Conferences
-
Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study). Conferences
-
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy. Conferences
-
LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). Conferences
-
Locoregional recurrence following pathologic complete response in patients with T1-3 N0 breast cancer treated with neoadjuvant chemotherapy, breast conserving surgery and whole breast radiation: Is a trial of omission of radiation warranted? Conferences
-
Multi-site implementation of patient-reported outcome measures for personalized care and patient activation in symptom management. Conferences
-
Multisystem immune-related adverse events from dual agent immunotherapy use Conferences
-
Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada Conferences
-
Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need. Conferences
-
Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada. Conferences
-
Patient preferences for treatment and outcomes in hormone-sensitive prostate cancer (HSPC). Conferences
-
Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RTOG 1203 Conferences
-
Phase I pharmacokinetic study of single agent trametinib in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study. Conferences
-
Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial. Conferences
-
Phase II study of cabozantinib in recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago and California Phase II Consortia. Conferences
-
Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer. Conferences
-
Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial Conferences
-
Pre-screening test for clinical trials of Autologous γδ T lymphocyte therapy for advanced cancer. Conferences
-
Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A Canadian multicenter analysis from the CHORD Consortium. Conferences
-
Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC). Conferences
-
Quality of end-of-life care for patients with multiple myeloma: A 12-year analysis of a population-based cohort. Conferences
-
Readmission and emergency department visits in the peri-treatment period for head and neck cancers patients in Ontario. Conferences
-
Reasons for delay in time to initiation of adjuvant chemotherapy (TTAC) for colon cancer (CC): Analysis from six academic centers in Ontario, Canada. Conferences
-
Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). Conferences
-
SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma. Conferences
-
Simultaneous versus staged resection for synchronous colorectal cancer liver metastases: A population-based cohort study. Conferences
-
Suggested reclassification strategy applied to intermediate and poor risk nonseminomatous germ cell tumors (NSGCT): A two-institution combined analysis. Conferences
-
The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement. Conferences
-
The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy. Conferences
-
The impact of a well breast cancer patient transition model of care on oncologists’ practice. Conferences
-
The impact of primary pancreatic tumor location on clinical outcomes in advanced disease: Results from the chord consortium. Conferences
-
The impact of routine ESAS use on overall survival: Results of a population-based retrospective matched cohort analysis. Conferences
-
Treatment outcomes for newly diagnosed, untreated TP53-mutated acute myeloid leukemia: A systematic review and meta-analysis. Conferences
-
Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada. Conferences
-
Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC. Conferences
-
Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study Conferences
-
Using cognitive interviews and expert feedback to validate the Australian AYA Distress Thermometer and Problem Checklist for use in Canada. Conferences
-
Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC). Conferences
-
Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421. Conferences
-
Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer? Conferences
-
weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration resistant prostate cancer. Conferences